<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 3.0.2.0 Copyright 1995 - 2014 Thomson Reuters Accelus. All rights reserved.-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:ebs="http://emergentbiosolutions.com/20140930" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="ebs-20140930.xsd" />
  <xbrli:context id="c20140101to20140930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130701to20130930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131211_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130731to20130801_BusinessAcquisitionAxis_HppdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-31</xbrli:startDate>
      <xbrli:endDate>2013-08-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseIntangibleAssetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_BusinessAcquisitionAxis_HppdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-20</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseIntangibleAssetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-20</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-20</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-20</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130731to20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-31</xbrli:startDate>
      <xbrli:endDate>2013-08-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-20</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-20</xbrli:startDate>
      <xbrli:endDate>2014-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130930_BusinessAcquisitionAxis_CangeneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HppdMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseIntangibleAssetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:CangeneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_BusinessAcquisitionAxis_HppdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_BusinessAcquisitionAxis_HppdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HppdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ebs:MorphosysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_TypeOfArrangementAxis_MorphosysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ebs:MorphosysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:MarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:MarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:MarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:RsdlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:BiodefenseProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_OtlertuzumabMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:OtlertuzumabMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesTherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:BiosciencesTherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_IxinityProductCandidatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ebs:IxinityProductCandidatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-01-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_LongtermDebtTypeAxis_EbsBamlTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:EbsBamlTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:RevolvingCreditLoanDatedDecember2013DueInDecember2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_LongtermDebtTypeAxis_EbsBamlTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:EbsBamlTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:RevolvingCreditLoanDatedDecember2013DueInDecember2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:RevolvingCreditLoanDatedDecember2013DueInDecember2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20141231_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:StockOptionsMemberMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:StockOptionsMemberMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:StockOptionsMemberMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:StockOptionsMemberMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:StockOptionsMemberMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:StockOptionsMemberMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AwardTypeAxis_StockOptionsMemberMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:StockOptionsMemberMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_AwardTypeAxis_StockOptionsMemberMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:StockOptionsMemberMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130930_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">ebs:OxfordEmergentTuberculosisConsortiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">ebs:OxfordEmergentTuberculosisConsortiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130701to20130930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130701to20130930_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130701to20130930_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140930_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130930_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130701to20130930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130930_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140701to20140930_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>ebs:Criteria</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U005">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U006">
    <xbrli:measure>ebs:AccountingUnit</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U007">
    <xbrli:measure>ebs:Institution</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U008">
    <xbrli:measure>ebs:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U009">
    <xbrli:measure>ebs:BusinessUnit</xbrli:measure>
  </xbrli:unit>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20140101to20140930">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20140101to20140930">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20140101to20140930">2014-09-30</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20140101to20140930">Yes</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20140101to20140930">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20140101to20140930">No</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20140101to20140930">Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20140101to20140930">Emergent BioSolutions Inc.</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20140101to20140930">0001367644</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20141031" unitRef="U001" decimals="0">37552024</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20140101to20140930">2014</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20140101to20140930">Q3</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20140101to20140930">10-Q</dei:DocumentType>
  <!--Accounts Receivable, Net, Current-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20140930" unitRef="U002" decimals="-3">44111000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts Receivable, Net, Current-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20131231" unitRef="U002" decimals="-3">60587000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts Receivable, Net-Morphosys [Member]-->
  <us-gaap:AccountsReceivableNet contextRef="c20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="0">450000</us-gaap:AccountsReceivableNet>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20131231" unitRef="U002" decimals="-3">27521000</us-gaap:AccountsPayableCurrent>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20140930" unitRef="U002" decimals="-3">39351000</us-gaap:AccountsPayableCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20131231" unitRef="U002" decimals="-3">1252000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20140930" unitRef="U002" decimals="-3">4688000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20131231" unitRef="U002" decimals="-3">-3465000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20140930" unitRef="U002" decimals="-3">-3810000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Weighted average amortization period-HPPD [Member]-->
  <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c20140101to20140930_BusinessAcquisitionAxis_HppdMember">P77M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20140930" unitRef="U002" decimals="-3">264877000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20131231" unitRef="U002" decimals="-3">247637000</us-gaap:AdditionalPaidInCapital>
  <!--Amortization of Financing Costs-->
  <us-gaap:AmortizationOfFinancingCosts contextRef="c20140101to20140930" unitRef="U002" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
  <!--Amortization of Financing Costs-->
  <us-gaap:AmortizationOfFinancingCosts contextRef="c20130701to20130930" unitRef="U002" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
  <!--Amortization of Financing Costs-->
  <us-gaap:AmortizationOfFinancingCosts contextRef="c20140701to20140930" unitRef="U002" decimals="-3">-203000</us-gaap:AmortizationOfFinancingCosts>
  <!--Amortization of Financing Costs-->
  <us-gaap:AmortizationOfFinancingCosts contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
  <!--Amortization of Intangible Assets-Biodefense Intangible Asset [Member]-Cangene [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember" unitRef="U002" decimals="-4">1000000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-HPPD [Member]-Biodefense Intangible Asset [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember" unitRef="U002" decimals="-6">0</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Cangene [Member]-Biosciences [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiosciencesMember" unitRef="U002" decimals="-4">1500000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Cangene [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-5">2600000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-HPPD [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20130101to20131231_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-5">3500000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Biodefense Intangible Asset [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember" unitRef="U002" decimals="0">425000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-HPPD [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20140930_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-5">1200000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Biosciences [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiosciencesMember" unitRef="U002" decimals="0">620000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Cangene [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-5">1000000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Biodefense Products [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember" unitRef="U002" decimals="-3">-1026000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-RSDL [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U002" decimals="-3">-2640000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Licensed Products [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U002" decimals="-3">-285000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Marketed Products [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember" unitRef="U002" decimals="-3">-502000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930" unitRef="U002" decimals="-3">-6084000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Contractual Rights [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="U002" decimals="-3">-423000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Manufacturing Agreement [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U002" decimals="-3">-870000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Intangible Assets-Corporate Trade Name [Member]-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3">-338000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Compensation Plan [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20140930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember" unitRef="U001" decimals="-5">1500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Compensation Plan [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20130101to20130930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember" unitRef="U001" decimals="-5">1500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Convertible debt [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20140930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5">8100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Compensation Plan [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140701to20140930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember" unitRef="U001" decimals="-5">1500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Compensation Plan [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20130701to20130930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember" unitRef="U001" decimals="-5">1400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20131231" unitRef="U002" decimals="-3">626630000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20140930" unitRef="U002" decimals="-3">869291000</us-gaap:Assets>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">37701000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">154669000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">37701000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20140930_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">154669000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20131231" unitRef="U002" decimals="-3">273115000</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20140930" unitRef="U002" decimals="-3">383632000</us-gaap:AssetsCurrent>
  <!--Prepaid expenses and other assets-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">2375000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
  <!--Accounts receivable-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">19649000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
  <!--Deferred taxes, net-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">18371000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">6378000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
  <!--Price paid per share of acquisition (in dollars per share)-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionSharePrice contextRef="c20131211_BusinessAcquisitionAxis_CangeneMember" unitRef="U003" decimals="INF">3.24</us-gaap:BusinessAcquisitionSharePrice>
  <!--Cash-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">43631000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <!--Pro Forma Information-->
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following pro forma information is presented as if the acquisition had occurred on January 1, 2013, and combines the historical results of operations of the Company and Cangene for the nine month periods ended September 30, 2014 and 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Pro forma revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;329,642&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;304,164&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Pro forma net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;9,109&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;468&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <!--Business Combination, Contingent Consideration, Liability-HPPD [Member]-->
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">-16232000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-Contract Manufacturing [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20130801_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U002" decimals="-5">3500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">32099000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-Biodefense Intangible Asset [Member]-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember" unitRef="U002" decimals="-3">20400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">40400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-HPPD [Member]-RSDL [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U002" decimals="-5">28600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-Corporate Trade Name [Member]-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3">2800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-Marketing-Related Intangible Assets [Member]-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember" unitRef="U002" decimals="-3">8300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-Licensed Products [Member]-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U002" decimals="-3">3300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill-Contract Manufacturing [Member]-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="U002" decimals="-3">5600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">11000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
  <!--Pro forma revenue-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c20140101to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">329642000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <!--Pro forma revenue-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c20130101to20130930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">304164000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <!--Pro forma net income-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c20140101to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">9109000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <!--Pro forma net income-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c20130101to20130930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">468000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <!--Transaction costs-Cangene [Member]-->
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-5">3700000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <!--Total purchase price-HPPD [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c20130731to20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">42105000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <!--Total purchase price-HPPD [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c20140101to20140930_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">42105000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <!--Total purchase price-Cangene [Member]-->
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">221800000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <!--Inventory-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3" id="Item-1">52619000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
  <!--Acquisitions-->
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2.&lt;/font&gt;&amp;#160;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cangene Corporation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On February 21, 2014, the Company acquired 100% of the voting interest of Cangene for $3.24 per share in cash (on a fully-diluted basis), which represents a total purchase price of $221.8 million. This transaction was accounted for by the Company under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of Cangene were recorded as of the acquisition date, at their respective fair values, and combined with those of the Company. This acquisition diversified the product portfolio of the Company's Biodefense and Biosciences divisions and expanded the Company's manufacturing capabilities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at February 21, 2014.&amp;#160;As of the date of this filing, the valuation of acquired intangible assets, deferred taxes and other fair value adjustments are not complete as the Company is obtaining and analyzing additional information related to the aforementioned items. As such, the purchase price allocation is subject to change.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;February 21, 2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Fair value of tangible assets acquired and liabilities assumed:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cash&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;43,631&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Accounts receivable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,649&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Inventory (i)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;52,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Prepaid expenses and other assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;40,264&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Deferred taxes, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;18,371&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Income tax receivable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,940&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(22,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Provision for chargebacks&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(2,447&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,089&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(6,378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total fair value of tangible assets acquired and liabilities assumed&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;147,017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Acquired in-process research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;40,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;25,883&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;221,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(i) Acquired inventory reflects a $6.2 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $6.2 million step-up is estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on expected inventory turnover, which will increase cost of product sales and contract manufacturing during such period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;During the three months ended September 30, 2014 the Company updated its fair value determination for contingent purchase consideration and the provision for chargebacks resulting in a reduction to goodwill of $5.9 million and a reduction to contingent purchase consideration and the provision of chargebacks.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: middle;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Period&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;( in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;in years&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Corporate Trade Name&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Marketed Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;10.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Licensed Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;7.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Biodefense Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;20,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;12.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Contract Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,600&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total identified intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;40,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company determined the estimated fair value of the intangible assets using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the Company's products.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;A portion of the assets acquired from Cangene consisted of intangible assets. The Marketed Products intangible asset consists of WinRho&lt;sup&gt;&amp;#174;&lt;/sup&gt; SDF [Rh&lt;sub&gt;o&lt;/sub&gt;(D) Immune Globulin Intravenous (Human)] and VARIZIG&lt;sup&gt;&amp;#174;&lt;/sup&gt; (Varicella Zoster Immune Globulin (Human)]. The Licensed Products intangible asset primarily consists of HepaGam B&lt;sup&gt;&amp;#174;&lt;/sup&gt; (Hepatitis B Immune Globulin Intravenous (Human). The Biodefense intangible asset consist of BAT&lt;sup&gt;TM&lt;/sup&gt; [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-Equine], AIGIV (Anthrax Immune Globulin Intravenous (Human)) and VIGIV (Vaccinia Immune Globulin Intravenous (Human)). The Contract Manufacturing intangible asset is primarily related to contract manufacturing contracts with current and expected future third-party customers.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company estimated the fair value of the Marketed, Licensed and Biodefense Product intangible assets using the income approach with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from these Marketed, Licensed and Biodefense Product intangible assets were based on key assumptions including: estimates of revenues and operating profits; the life of the potential commercialized product and associated risks; and risks related to the viability of and potential alternative treatments in any future target markets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company estimated the fair value of the Contract Manufacturing intangible asset using the income approach with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value this intangible asset. The projected cash flows from the Contract Manufacturing intangible asset were based on key assumptions including: estimates of revenues and operating profits; and viability of attaining/maintaining future third-party manufacturing relationships with the Company's customers.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company estimated the fair value of the Corporate Trade Name intangible asset using the relief of royalty method with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value this intangible asset.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The weighted average amortization period of the intangible assets from the Cangene acquisition is 115 months. For the three and nine months ended September 30, 2014, the Company recorded amortization expense of $1.0 million and $2.6 million, respectively, for intangible assets acquired from Cangene, which has been recorded in cost of product sales and contract manufacturing. Amortization expense of $620,000 and $1.5 million, respectively, was recorded within the Biosciences segment for the three and nine months ended September 30, 2014. Amortization expense of $425,000 and $1.0 million, respectively, was recorded within the Biodefense segment for the three and nine months ended September 30, 2014.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The intangible asset associated with in-process research and development ("IPR&amp;amp;D") acquired from Cangene is the IXINITY product candidate. Management determined that the estimated acquisition-date fair value of intangible assets related to IPR&amp;amp;D was $8.5 million. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. The Company estimated the fair value using a present value discount rate of 16%, which is based on the estimated weighted-average cost of capital for companies with that profiles substantially similar to that of Cangene and IPR&amp;amp;D assets at a similar stage of development as IXINITY. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value the IPR&amp;amp;D. The projected cash flows for IXINITY was based on key assumptions including: estimates of revenues and operating profits, considering its stage of development on the acquisition date; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a product candidate, such as obtaining marketing approval from the U.S. Food and Drug Administration ("FDA") and other regulatory agencies; and risks related to the viability of and potential for alternative treatments in any future target markets. IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts (see Note 6).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company recorded approximately $25.9 million in goodwill related to the Cangene acquisition, representing the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired. None of the goodwill generated from the Cangene acquisition is expected to be deductible for tax purposes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company has incurred transaction costs related to the Cangene acquisition of approximately $3.7 million for the nine months ended September 30, 2014, which has been recorded in selling, general and administrative expenses within the Company's Biosciences segment. The Company has incurred to date a total of $7.0 million in transaction costs associated with the Cangene acquisition&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;through September 30, 2014, of which $3.3 million was incurred in the second half of 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;From the date of acquisition to September 30, 2014, the Company has recognized revenue of $82.1 million and a net loss attributable to Emergent BioSolutions Inc. of $4.8 million from the operations of Cangene.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following pro forma information is presented as if the acquisition had occurred on January 1, 2013, and combines the historical results of operations of the Company and Cangene for the nine month periods ended September 30, 2014 and 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Pro forma revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;329,642&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;304,164&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Pro forma net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;9,109&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;468&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Healthcare Protective Products Division&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On August 1, 2013, the Company acquired substantially all of the assets and liabilities of Healthcare Protective Products Division ("HPPD"), a division of Bracco Diagnostics Inc. ("Bracco"), for $25.9 million in cash along with contingent purchase consideration obligations to Bracco. The assets and liabilities acquired include HPPD's product, RSDL, and a majority of the customer and distributor agreements associated with RSDL along with $1.5 million of manufacturing equipment. In addition, the Company assumed a $1.5 million liability associated with the Canadian Technology Development Fund ("TDF"). The acquisition diversified the product portfolio of the Biodefense segment by adding product sales from RSDL.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The contingent purchase consideration obligation due to Bracco is based on a percentage of RSDL net sales, ranging from 5-10%, for the period August 1, 2013 through July 31, 2028. At August 1, 2013, the contingent purchase consideration obligation was recorded at a fair value of $16.2 million. The Level 3 fair value of this obligation is based on management's assessment of the potential future realization of the contingent purchase consideration payments. This assessment is based on inputs that have no observable market. The obligation is measured using the income approach (a discounted cash flow model).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The total purchase price is summarized below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Amount of cash paid to Bracco Diagnostics Inc.&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;25,873&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Fair value of contingent purchase consideration at date of acquisition&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,232&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;42,105&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The table below summarizes the allocation of the purchase price based upon fair values of assets acquired and liabilities assumed at August 1, 2013.&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;32,099&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;9,916&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Acquired equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;1,543&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;11&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Assumed liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,464&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;42,105&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;During the nine months ended September 30, 2014, the Company updated its purchase price to include an assumed liability from the TDF resulting in additional goodwill of $1.5 million.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;A substantial portion of the assets acquired from Bracco consisted of intangible assets associated with RSDL. &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As of the date of acquisition, the Company recorded intangible assets of approximately &lt;/font&gt;$28.6 million &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;related to RSDL, which is being amortized over 8 years, and &lt;/font&gt;$3.5 million &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;related to a manufacturing agreement with Bracco, which is being amortized over 3 years. For the three and nine months ended September 30, 2014, the Company recorded $1.2 million and &lt;/font&gt;$3.5 million, respectively, of&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt; amortization expense for intangible assets acquired from Bracco which was recorded in &lt;/font&gt;cost of product sales and contract manufacturing within the Company's Biodefense segment&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;. The weighted average remaining amortization period for the intangible assets is 77 months.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company recorded approximately $9.9 million in goodwill related to the HPPD acquisition representing the purchase price paid in the acquisition in excess of the fair value of the tangible and intangible assets acquired. This goodwill is included in the Company's biodefense segment. None of the goodwill generated from the HPPD acquisition is expected to be deductible for tax purposes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company has determined the historical results of HPPD were not significant to the Company's results of operations, and as such no proforma disclosures have been presented.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <!--Property, plant and equipment-HPPD [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">1543000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <!--Property, plant and equipment-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">40264000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net-Cangene [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">147017000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <!--Inception to date transaction costs-Cangene [Member]-->
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c20140701to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-5">7000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
  <!--Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual-HPPD [Member]-->
  <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual contextRef="c20140701to20140930_BusinessAcquisitionAxis_HppdMember" unitRef="U002" xsi:nil="true" />
  <!--Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual-Cangene [Member]-->
  <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual contextRef="c20140101to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-5">4800000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
  <!--Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual-HPPD [Member]-->
  <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c20140701to20140930_BusinessAcquisitionAxis_HppdMember" unitRef="U002" xsi:nil="true" />
  <!--Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual-Cangene [Member]-->
  <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c20140101to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-5">82100000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20130101to20130930" unitRef="U002" decimals="-3">30895000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20140101to20140930" unitRef="U002" decimals="-3">62911000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20131231" unitRef="U002" decimals="-3">179338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20140930" unitRef="U002" decimals="-3">242249000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20121231" unitRef="U002" decimals="-3">141666000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20130930" unitRef="U002" decimals="-3">172561000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" id="Item-2">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" id="Item-3">154669000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" id="Item-4">37701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" id="Item-5">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20140930_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" id="Item-6">154669000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" id="Item-7">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" id="Item-8">37701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3" id="Item-9">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Description of rights and obligations-Morphosys [Member]-->
  <us-gaap:CollaborativeArrangementRightsAndObligations contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember">MorphoSys and the Company will jointly fund further development of MOR209/ES414, with the Company responsible for 36% of the total development cost and MorphoSys responsible for the remainder</us-gaap:CollaborativeArrangementRightsAndObligations>
  <!--Collaborative Arrangement Disclosure [Text Block]-->
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;4. MorphoSys collaboration agreement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In August 2014, the Company entered into a collaboration agreement ("MorphoSys Agreement") with MorphoSys for the joint worldwide development and commercialization of MOR209/ES414, a targeted immunotherapeutic protein, constructed using the Company's proprietary ADAPTIR technology platform, which activates host T-cell immunity specifically against prostate cancer cells expressing prostate specific membrane antigen, an antigen commonly overexpressed on prostate cancer cells.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In accordance with the terms of the MorphoSys Agreement, the Company received a nonrefundable $20 million upfront payment and may receive up to $163 million in additional contingent payments, of which $80.0 million and $83.0 million, respectively, are due upon the achievement of specified development and regulatory milestones. The Company has determined that payments for the achievement of the development and regulatory milestones identified in the agreement that may become due will be deemed substantive milestones and will be accounted for as revenue in the period in which the milestone is achieved.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;MorphoSys and the Company will jointly fund further development of MOR209/ES414, with the Company responsible for 36% of the total development cost and MorphoSys responsible for the remainder. The Company's funding requirement is capped at $186 million. The Company will retain commercialization rights in the U.S. and Canada, with a tiered royalty obligation to MorphoSys, ranging from mid-single digits up to 20%. MorphoSys will gain worldwide commercialization rights excluding the U.S. and Canada, with a low single digit royalty obligation to the Company.The Company's current obligations under the collaboration includes the performance of non-clinical, clinical, manufacturing and regulatory activities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company has evaluated the MorphoSys Agreement and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.The Company determined there were two units of accounting under the collaboration agreement with MorphoSys: (1) the delivered license to further develop and commercialize MOR209/ES414 and (2) undelivered items related to development services. The Company determined that the license had standalone value as the drug candidate has been developed and is currently Phase I clinical trial ready, MorphoSys possesses the knowledge, technology, skills, experience and infrastructure necessary to complete all further development of the drug through commercialization, and additionally MorphoSys has the right to further sublicense the product. The Company allocated the $20 million upfront payment to the two units of accounting using the relative selling price method. The Company determined the estimated selling price for the license using the income approach and a discount rate of 12%. The estimated selling price includes unobservable inputs (Level 3), such as estimates of revenues and operating margins; the time and resources needed to complete the development and approval of the product candidate; and the risk related to the viability of and potential for alternative treatments. The Company determined the estimated selling price of the development services unit of accounting based on the estimated number of full-time equivalent personnel at the contractual rate as defined in the MorphoSys Agreement, which represents the approximate terms of other service related contracts both entered by the Company and observed generally through other collaboration negotiations. The allocation resulted in $15.3 million of the upfront payment being allocated to the license and $4.7 million being allocated to the development services. The Company determined the license fee unit of accounting was delivered on the date the MorphoSys agreement was executed and therefore has recognized revenue of $15.3 million, which is included in contracts, grants and collaborations revenues within the Company's Biosciences segment. Revenue related to the undelivered item will be recognized as the services are performed. The current estimated service period for the undelivered item under the MorphoSys Agreement is through 2022.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The amount allocable to the units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the noncontingent amount). As such, the Company excluded from the allocable arrangement consideration the milestone payments and royalties regardless of the probability of receipt.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As of September 30, 2014, accounts receivable related to the MorphoSys Agreement was $450,000. As of September 30, 2014, deferred revenue related to the MorphoSys Agreement consisted of $590,000 and $4.1 million of current and long-term deferred revenue, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20140930" unitRef="U002" xsi:nil="true" />
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20131231" unitRef="U002" xsi:nil="true" />
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20131231" unitRef="U003" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20140930" unitRef="U003" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, $0.001 par value; 100,000,000 shares authorized, 37,960,977 shares issued and 37,548,024, shares outstanding at September 30, 2014; 37,036,996 shares issued and 36,624,043, shares outstanding at December 31, 2013-->
  <us-gaap:CommonStockValue contextRef="c20140930" unitRef="U002" decimals="-3">38000</us-gaap:CommonStockValue>
  <!--Common stock, $0.001 par value; 100,000,000 shares authorized, 37,960,977 shares issued and 37,548,024, shares outstanding at September 30, 2014; 37,036,996 shares issued and 36,624,043, shares outstanding at December 31, 2013-->
  <us-gaap:CommonStockValue contextRef="c20131231" unitRef="U002" decimals="-3">37000</us-gaap:CommonStockValue>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20140930" unitRef="U001" decimals="0">37960977</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20131231" unitRef="U001" decimals="0">37036996</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20131231" unitRef="U001" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20140930" unitRef="U001" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20140930" unitRef="U001" decimals="0">37548024</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20131231" unitRef="U001" decimals="0">36624043</us-gaap:CommonStockSharesOutstanding>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20140701to20140930" unitRef="U002" decimals="-3">21273000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20140101to20140930" unitRef="U002" decimals="-3">6280000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130101to20130930" unitRef="U002" decimals="-3">16540000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130701to20130930" unitRef="U002" decimals="-3">13502000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Basis of presentation and consolidation-->
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Basis of presentation and consolidation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 3pt; font-size: 10pt;"&gt;In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of September 30, 2014; the results of operations and comprehensive income for the three and nine months ended September 30, 2014 and 2013; and cash flows for the nine months ended September 30, 2014 and 2013. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 3pt; font-size: 10pt;"&gt;There have been no significant changes to the Company's summary of significant accounting policies, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC, during the nine months ended September 30, 2014, except for additions to the Company's accounting policies for revenue recognition and inventories related to the Cangene Corporation ("Cangene") acquisition (Note 2) and revenue recognition for the MorphoSys AG ("MorphoSys") collaboration (Note 4).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <!--Contracts, grants and collaborations-->
  <us-gaap:ContractsRevenue contextRef="c20130701to20130930" unitRef="U002" decimals="-3">12805000</us-gaap:ContractsRevenue>
  <!--Contracts, grants and collaborations-->
  <us-gaap:ContractsRevenue contextRef="c20140101to20140930" unitRef="U002" decimals="-3">82324000</us-gaap:ContractsRevenue>
  <!--Contracts, grants and collaborations-->
  <us-gaap:ContractsRevenue contextRef="c20130101to20130930" unitRef="U002" decimals="-3">42386000</us-gaap:ContractsRevenue>
  <!--Contracts, grants and collaborations-->
  <us-gaap:ContractsRevenue contextRef="c20140701to20140930" unitRef="U002" decimals="-3">44064000</us-gaap:ContractsRevenue>
  <!--Cost of Goods Sold-->
  <us-gaap:CostOfGoodsSold contextRef="c20130701to20130930" unitRef="U002" decimals="-3">20063000</us-gaap:CostOfGoodsSold>
  <!--Cost of Goods Sold-->
  <us-gaap:CostOfGoodsSold contextRef="c20130101to20130930" unitRef="U002" decimals="-3">42706000</us-gaap:CostOfGoodsSold>
  <!--Cost of Goods Sold-->
  <us-gaap:CostOfGoodsSold contextRef="c20140101to20140930" unitRef="U002" decimals="-3">85927000</us-gaap:CostOfGoodsSold>
  <!--Cost of Goods Sold-->
  <us-gaap:CostOfGoodsSold contextRef="c20140701to20140930" unitRef="U002" decimals="-3">32423000</us-gaap:CostOfGoodsSold>
  <!--Face amount of debt instrument-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtInstrumentFaceAmount contextRef="c20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U002" decimals="-5">250000000</us-gaap:DebtInstrumentFaceAmount>
  <!--Debt and Capital Leases Disclosures [Text Block]-->
  <us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;7.&lt;/font&gt;&amp;#160;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On January 29, 2014, the Company issued $250.0 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the "Notes"). The Notes bear interest at a rate of 2.875% per year, payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2014. The Notes mature on January 15, 2021, unless earlier purchased by the Company or converted. The conversion rate is equal to 30.8821 shares of common stock per $1,000 principal amount of notes (which is equivalent to an initial conversion price of approximately $32.38 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain specified events but will not be adjusted for accrued and unpaid interest. The Company incurred approximately $8.3 million in debt issuance costs associated with the Notes, which has been capitalized on the consolidated balance sheets and is being amortized over seven years, using the effective interest method.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On December 11, 2013, the Company entered into a senior secured credit agreement (the "Credit Agreement") with three lending financial institutions (the "Lenders"), led by Bank of America, N.A., as administrative agent. The Credit Agreement originally provided for a revolving credit facility of up to $100.0 million through December 11, 2018 (or such earlier date required by the terms of the Credit Agreement) and a term loan facility of up to $125.0 million to be drawn in full, if at all, on or prior to March 31, 2014. In connection with the Credit Agreement,&amp;#160;the Company borrowed $62.0 million under the revolving credit facility primarily to repay obligations under existing loan agreements. On January 29, 2014, in connection with the Company's issuance of the Notes, the unused $125.0 million term loan portion of the Credit Agreement terminated automatically in accordance with the terms of the Credit Agreement. In addition, following the closing of the Notes offering, the Company repaid the $62.0 million outstanding indebtedness under the revolving credit facility, which restored the full $100.0 million revolving credit capacity under this facility. In addition, during the nine months ended September 30, 2014, the Company expensed $1.8 million of debt issuance cost associated with the term loan facility. As of September 30, 2014, no amounts were drawn under the revolving credit facility.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company's payment obligations under the Credit Agreement are secured by a lien on substantially all of the Company's assets, including the stock of all of the Company's subsidiaries, and the assets of the subsidiary guarantors, including mortgages over certain of their real properties, including the Company's large-scale vaccine manufacturing facility in Lansing, Michigan and the Company's product development and manufacturing facility in Baltimore, Maryland.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Credit Agreement, as amended, contains affirmative and negative covenants customary for financings of this type. Negative covenants in the Credit Agreement limit the Company's ability to, among other things: incur indebtedness (other than the issuance of the Notes) and liens; dispose of assets; make investments including loans, advances or guarantees; and enter into certain mergers or similar transactions. The Credit Agreement also contains financial covenants, tested quarterly and in connection with any triggering events under the Credit Agreement that include the maintenance of: (1) a minimum consolidated debt service coverage ratio of 2.50 to 1.00, (2) a maximum consolidated leverage ratio for the period ending on or prior to September 30, 2014 of 4.00 to 1.00, for the measurement period ending December 31, 2014 of 3.75 to 1.00, and thereafter of 3.50 to 1.00, (3) a maximum consolidated senior leverage ratio of 2.00 to 1.00 and (4) a minimum liquidity requirement of $50 million. Upon the occurrence and continuance of an event of default under the Credit Agreement, the commitments of the lenders to make loans under the Credit Agreement may be terminated and the Company's payment obligations under the Credit Agreement may be accelerated. The events of default under the Credit Agreement include, among others, subject in some cases to specified cure periods: payment defaults; inaccuracy of representations and warranties in any material respect; defaults in the observance or performance of covenants; bankruptcy and insolvency related defaults; the entry of a final judgment in excess of a threshold amount; change of control; and the invalidity of loan documents relating to the Credit Agreement.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock>
  <!--Conversion price per share (in dollars per share)-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U003" decimals="INF">32.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <!--Debt issuance costs-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtIssuanceCosts contextRef="c20140101to20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U002" decimals="-5">8300000</us-gaap:DebtIssuanceCosts>
  <!--Interest rate, stated percentage (in hundredths)-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U005" decimals="INF">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <!--Maturity date-EBS BAML Term Loan [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20140101to20140930_LongtermDebtTypeAxis_EbsBamlTermLoanMember">2018-12-11</us-gaap:DebtInstrumentMaturityDate>
  <!--Maturity date-Revolving Credit Loan dated December 2013, due in December 2018 [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20140101to20140930_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member">2018-12-11</us-gaap:DebtInstrumentMaturityDate>
  <!--Maturity date-Convertible Senior Notes Due 2021 [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20140101to20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member">2021-01-15</us-gaap:DebtInstrumentMaturityDate>
  <!--Current and deferred income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20130101to20130930" unitRef="U002" decimals="-3">4667000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Current and deferred income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20140101to20140930" unitRef="U002" decimals="-3">1817000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred revenue, current portion-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20131231" unitRef="U002" decimals="-3">1834000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current portion-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20140930" unitRef="U002" decimals="-3">5813000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, current portion-Morphosys [Member]-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="0">590000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue, net of current portion-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20140930" unitRef="U002" decimals="-3">5815000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, net of current portion-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20131231" unitRef="U002" decimals="-3">0</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue, net of current portion-Morphosys [Member]-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="-5">4100000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Noncurrent-->
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="c20131231" unitRef="U002" decimals="-3">0</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Noncurrent-->
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="c20140930" unitRef="U002" decimals="-3">17043000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <!--Deferred tax liability long-term, net-->
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="c20131231" unitRef="U002" decimals="-3">1419000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <!--Deferred tax liability long-term, net-->
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="c20140930" unitRef="U002" decimals="-3">0</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <!--Deferred tax liability-current portion, net-->
  <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="c20131231" unitRef="U002" decimals="-3">88000</us-gaap:DeferredTaxLiabilitiesCurrent>
  <!--Deferred tax liability-current portion, net-->
  <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="c20140930" unitRef="U002" decimals="-3">88000</us-gaap:DeferredTaxLiabilitiesCurrent>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20140101to20140930" unitRef="U002" decimals="-3">24286000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20130101to20130930" unitRef="U002" decimals="-3">13547000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Equity awards-->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;8. &lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Equity awards&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As of September 30, 2014, the Company had two stock-based employee compensation plans, the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan") (together, the "Emergent Plans").&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On May 22, 2014, the Company's shareholders approved an amendment to the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 4,000,000. As part of this amendment, awards of restricted stock units granted after May 22, 2014 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 2.3 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 1,000,000.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following is a summary of stock option award activity under the Emergent Plans:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2006 Plan&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2004 Plan&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: ''Times New Roman'', Times, serif; margin-left: 9pt; font-size: 10pt;"&gt;Outstanding at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,633,146&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;17.01&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;53,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;23,148,738&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.55pt; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;1,116,721&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;27.49&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.55pt; font-size: 10pt;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(663,256&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16.66&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.55pt; font-size: 10pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(92,549&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19.69&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: ''Times New Roman'', Times, serif; margin-left: 9pt; font-size: 10pt;"&gt;Outstanding at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,994,062&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19.94&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;53,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;14,289,421&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: ''Times New Roman'', Times, serif; margin-left: 9pt; font-size: 10pt;"&gt;Exercisable at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,086,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;17.76&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;53,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;9,446,930&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following is a summary of restricted stock unit award activity under the 2006 Plan:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Grant Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Outstanding at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;789,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16.53&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;18,246,611&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;558,362&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;27.49&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Vested&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(345,072&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;17.76&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(44,275&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19.66&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Outstanding at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;958,966&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;22.32&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;20,435,565&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!--Earnings Per Share [Text Block]-->
  <us-gaap:EarningsPerShareTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;10. Earnings per share&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For the three and nine month periods ended September 30, 2014 and 2013, basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For the three and nine month periods ended September 30, 2014, diluted earnings per share is computed using the if-converted method by dividing the adjusted net income by the weighted average number of shares of common stock outstanding during the period. The adjusted net income is adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the Company's Notes. The weighted average number of shares-diluted is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For the three and nine months ended September 30, 2013, diluted earnings per share is computed using the treasury method by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following table presents the calculation of basic and diluted net income per share:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Nine Months Ended September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands, except share and per share data)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;21,832&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;13,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;6,625&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,913&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Interest expense applicable to convertible debt, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;917&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Amortization of debt issuance costs, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;203&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Adjusted net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;22,952&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;13,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;6,625&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,913&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Weighted-average number of shares&amp;#8212;basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,507,220&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;36,272,579&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,261,357&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;36,129,183&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Dilutive securities&amp;#8212;equity awards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;954,639&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;742,950&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;623,837&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;375,047&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Dilutive securities&amp;#8212;convertible debt&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,095,304&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Weighted-average number of shares&amp;#8212;diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;46,557,163&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,015,529&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,885,194&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;36,504,230&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Income per share-basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.58&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.37&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.18&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.44&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Income per share-diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.49&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.36&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.17&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.44&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For the nine months ended September 30, 2014, there were no adjustments to adjusted net income or dilutive securities associated with the Company's Notes as such adjustments would have been anti-dilutive. For the nine months ended September 30, 2014, outstanding stock options to purchase approximately 1.5 million shares of common stock, along with 8.1 million shares related to the Company's convertible debt, were excluded from the calculation of diluted earnings per share.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Stock options with exercise prices in excess of the average per share closing price during the period are not considered in the calculation of fully diluted earnings per share. For the three months ended September 30, 2014, approximately 1.5 million stock options were excluded from the calculation of diluted earnings per share. For the three and nine month periods ended September 30, 2013, approximately 1.4 million and 1.5 million stock options, respectively, were excluded from the calculation of diluted earnings per share.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <!--Earnings Per Share, Basic-->
  <us-gaap:EarningsPerShareBasic contextRef="c20130101to20130930" unitRef="U003" decimals="2">0.44</us-gaap:EarningsPerShareBasic>
  <!--Earnings Per Share, Basic-->
  <us-gaap:EarningsPerShareBasic contextRef="c20130701to20130930" unitRef="U003" decimals="2">0.37</us-gaap:EarningsPerShareBasic>
  <!--Earnings Per Share, Basic-->
  <us-gaap:EarningsPerShareBasic contextRef="c20140701to20140930" unitRef="U003" decimals="2">0.58</us-gaap:EarningsPerShareBasic>
  <!--Earnings Per Share, Basic-->
  <us-gaap:EarningsPerShareBasic contextRef="c20140101to20140930" unitRef="U003" decimals="2">0.18</us-gaap:EarningsPerShareBasic>
  <!--Income per share - diluted-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20130701to20130930" unitRef="U003" decimals="2">0.36</us-gaap:EarningsPerShareDiluted>
  <!--Income per share - diluted-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20140701to20140930" unitRef="U003" decimals="2">0.49</us-gaap:EarningsPerShareDiluted>
  <!--Income per share - diluted-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20140101to20140930" unitRef="U003" decimals="2">0.17</us-gaap:EarningsPerShareDiluted>
  <!--Income per share - diluted-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20130101to20130930" unitRef="U003" decimals="2">0.44</us-gaap:EarningsPerShareDiluted>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20140101to20140930" unitRef="U002" decimals="-3">17000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20130101to20130930" unitRef="U002" decimals="-3">6000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Employee-related Liabilities, Current-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c20140930" unitRef="U002" decimals="-3">26850000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Employee-related Liabilities, Current-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c20131231" unitRef="U002" decimals="-3">24615000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Excess Tax Benefit from Share-based Compensation, Operating Activities-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="c20140101to20140930" unitRef="U002" decimals="-3">5566000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <!--Excess Tax Benefit from Share-based Compensation, Operating Activities-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="c20130101to20130930" unitRef="U002" decimals="-3">1949000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <!--Excess tax benefits from stock-based compensation-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="c20140101to20140930" unitRef="U002" decimals="-3">5566000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <!--Excess tax benefits from stock-based compensation-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="c20130101to20130930" unitRef="U002" decimals="-3">1949000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <!--Additions-Biodefense Products [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember" unitRef="U002" decimals="-3">20400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Manufacturing Agreement [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U002" decimals="-3">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Marketed Products [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember" unitRef="U002" decimals="-3">8300000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Contractual Rights [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="U002" decimals="-3">5600000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Corporate Trade Name [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3">2800000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-RSDL [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U002" decimals="-3">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-Licensed Products [Member]-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140701to20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U002" decimals="-3">3300000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Additions-->
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c20140701to20140930" unitRef="U002" decimals="-3">40400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c20140101to20140930" unitRef="U002" decimals="-3">1691000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <!--Present value discount rate (in hundredths)-Cangene [Member]-->
  <us-gaap:FairValueInputsDiscountRate contextRef="c20140701to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U005" decimals="2">0.16</us-gaap:FairValueInputsDiscountRate>
  <!--Transfers in/(out) of Level 3-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 contextRef="c20140101to20140930" unitRef="U002" decimals="-3">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c20131231" unitRef="U002" decimals="-3">16619000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c20140930" unitRef="U002" decimals="-3">19233000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <!--Fair Value Disclosures [Text Block]-->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;3.&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair value measurements&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&amp;#160;The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;154,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;154,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;154,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;154,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #ffffff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For the periods ended September 30, 2014 and 2013, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The fair value of contingent purchase consideration obligations are based on management's assessment of changes as a result of adjustments to the discount rates and updates in the assumed and actual achievement of future net sales for RSDL and HepaGam B, which are inputs that have no observable market (Level 3). For the three and nine months ended September 30, 2014, the contingent purchase consideration obligation increased by $1.6 million and&amp;#160; $3.2 million, respectively, primarily due to an adjustment to the actual and expected timing of RSDL and HepaGam B sales. This increase resulted in a charge that is classified in the Company's statement of operations as cost of product sales and contract manufacturing.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 8pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 8pt; font-size: 10pt;"&gt;The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2014.&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Expense (income) included in earnings&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,216&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,691&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Purchases, sales and issuances&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;1,089&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Transfers in/(out) of Level 3&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a nonrecurring basis. During the nine months ended September 30, 2014, the assets acquired and liabilities assumed as part of the Cangene acquisition (Note 2) and the evaluation of the IXINITY IPR&amp;amp;D asset for impairment (Note 6) were measured at fair value on a nonrecurring basis. During the nine months ended September 30, 2013, the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <!--Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)-->
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 8pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 8pt; font-size: 10pt;"&gt;The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2014.&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Expense (income) included in earnings&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,216&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Settlements&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,691&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Purchases, sales and issuances&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;1,089&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Transfers in/(out) of Level 3&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <!--Expense (income) included in earnings-->
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c20140101to20140930" unitRef="U002" decimals="-3">3216000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <!--Finite-Lived Intangible Asset, Useful Life-Biodefense Intangible Asset [Member]-Cangene [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseIntangibleAssetMember">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Asset, Useful Life-Marketing-Related Intangible Assets [Member]-Cangene [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketingRelatedIntangibleAssetsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Asset, Useful Life-HPPD [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20130731to20130801_BusinessAcquisitionAxis_HppdMember">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Asset, Useful Life-Cangene [Member]-Contract Manufacturing [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Asset, Useful Life-HPPD [Member]-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20130731to20130801_BusinessAcquisitionAxis_HppdMember_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Asset, Useful Life-Cangene [Member]-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Asset, Useful Life-Cangene [Member]-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140220to20140221_BusinessAcquisitionAxis_CangeneMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Asset, Useful Life-HPPD [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20140101to20140930_BusinessAcquisitionAxis_HppdMember">P115M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Assets, Gross-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biodefense Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Marketed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231" unitRef="U002" decimals="-3">32099000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U002" decimals="-3">28621000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U002" decimals="-3">3478000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="U002" decimals="-3">5600000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140930" unitRef="U002" decimals="-3">72499000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Marketed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember" unitRef="U002" decimals="-3">8300000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3">2800000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U002" decimals="-3">3300000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U002" decimals="-3">3478000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U002" decimals="-3">28621000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-Biodefense Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember" unitRef="U002" decimals="-3">20400000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U002" decimals="-3">-483000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231" unitRef="U002" decimals="-3">-1951000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Marketed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U002" decimals="-3">-1468000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biodefense Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20131231_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember" unitRef="U002" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U002" decimals="-3">-1353000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140930" unitRef="U002" decimals="-3">-8035000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Biodefense Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember" unitRef="U002" decimals="-3">-1026000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3">-338000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="U002" decimals="-3">-423000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U002" decimals="-3">-4108000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U002" decimals="-3">-285000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-Marketed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember" unitRef="U002" decimals="-3">-502000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Net book value of intangible assets-Contractual Rights [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="U002" decimals="-3">5177000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Licensed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="U002" decimals="-3">3015000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Biodefense Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_BiodefenseProductsMember" unitRef="U002" decimals="-3">19374000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930" unitRef="U002" decimals="-3">64464000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Otlertuzumab [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_OtlertuzumabMember" unitRef="U002" decimals="-5">41800000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Corporate Trade Name [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U002" decimals="-3">2462000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Biosciences Therapeutics [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_BiosciencesTherapeuticsMember" unitRef="U002" decimals="-5">50300000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-IXinity product candidates [Member]-Biosciences [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_StatementBusinessSegmentsAxis_BiosciencesMember_SubsegmentsAxis_IxinityProductCandidatesMember" unitRef="U002" decimals="-5">8500000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-RSDL [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_RsdlMember" unitRef="U002" decimals="-3">24513000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Manufacturing Agreement [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_ManufacturingAgreementMember" unitRef="U002" decimals="-3">2125000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Net book value of intangible assets-Marketed Products [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20140930_FiniteLivedIntangibleAssetsByMajorClassAxis_MarketedProductsMember" unitRef="U002" decimals="-3">7798000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Goodwill, Other Changes-Cangene [Member]-->
  <us-gaap:GoodwillOtherChanges contextRef="c20140101to20140930_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-5">5900000</us-gaap:GoodwillOtherChanges>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20140930" unitRef="U002" decimals="-3">41301000</us-gaap:Goodwill>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20131231" unitRef="U002" decimals="-3">13954000</us-gaap:Goodwill>
  <!--Goodwill-HPPD [Member]-->
  <us-gaap:Goodwill contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">9916000</us-gaap:Goodwill>
  <!--Goodwill-Cangene [Member]-->
  <us-gaap:Goodwill contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">25883000</us-gaap:Goodwill>
  <!--Intangible assets, in-process research and development and goodwill-->
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;6.&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intangible assets, in-process research and development and goodwill&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As of September 30, 2014, the Company had $50.3 million of IPR&amp;amp;D assets, which are included in the Biosciences business segment. This includes $41.8 million related to the Company's otlertuzumab product candidate and $8.5 million related to the Company's IXINITY product candidate. On July 29, 2014, the FDA issued a complete response letter for the New Drug Application ("NDA") of IXINITY. The complete response letter requested additional analyses of data from completed studies and noted deficiencies in the chemistry, manufacturing, and controls section of the license application, all of which must be resolved before approval can be granted by the FDA. The Company determined that the FDA's response to its NDA is a potential indicator of impairment of the related IXINITY IPR&amp;amp;D asset. The Company performed its interim impairment analysis and concluded its estimated fair value for the IXINITY IPR&amp;amp;D asset was in excess of carrying value, therefore the Company determined there was no impairment of the IXINITY IPR&amp;amp;D asset as of September 30, 2014. The determination of fair value involved unobservable inputs, such as estimates of future revenues and operating profits, probabilities of success and discount rates. The Company believes these inputs represent the highest and best use of the IXINITY IPR&amp;amp;D asset.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 3pt; font-size: 10pt;"&gt;Intangible assets consist of the following:&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Corporate&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Marketed&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Licensed&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Contract&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;RSDL&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Agreement&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Tradename&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cost basis&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;28,621&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;32,099&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;20,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,600&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;40,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;28,621&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;20,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,600&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;72,499&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,468&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(483&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 15px;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(2,640&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(870&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(338&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(285&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,026&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(423&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(6,084&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(4,108&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,353&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(338&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(285&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,026&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(423&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(8,035&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net book value at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;24,513&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,125&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,462&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;7,798&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,374&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,177&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;64,464&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 3pt; font-size: 10pt;"&gt;The following table is a summary of changes in goodwill:&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cost basis&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;13,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;27,347&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;41,301&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <!--Goodwill, Gross-->
  <us-gaap:GoodwillGross contextRef="c20131231" unitRef="U002" decimals="-3">13954000</us-gaap:GoodwillGross>
  <!--Goodwill, Gross-->
  <us-gaap:GoodwillGross contextRef="c20140930" unitRef="U002" decimals="-3">41301000</us-gaap:GoodwillGross>
  <!--Goodwill, Acquired During Period-->
  <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c20140701to20140930" unitRef="U002" decimals="-3">27347000</us-gaap:GoodwillAcquiredDuringPeriod>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20130701to20130930" unitRef="U002" decimals="-3">18293000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20140701to20140930" unitRef="U002" decimals="-3">29701000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20130101to20130930" unitRef="U002" decimals="-3">19709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20140101to20140930" unitRef="U002" decimals="-3">8754000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20140701to20140930" unitRef="U002" decimals="-3">7869000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20130101to20130930" unitRef="U002" decimals="-3">4667000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20140101to20140930" unitRef="U002" decimals="-3">2129000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20130701to20130930" unitRef="U002" decimals="-3">4802000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income tax receivable, net-->
  <us-gaap:IncomeTaxesReceivable contextRef="c20131231" unitRef="U002" decimals="-3">5651000</us-gaap:IncomeTaxesReceivable>
  <!--Income tax receivable, net-->
  <us-gaap:IncomeTaxesReceivable contextRef="c20140930" unitRef="U002" decimals="-3">8262000</us-gaap:IncomeTaxesReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20130101to20130930" unitRef="U002" decimals="-3">-65950000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-36106000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20130101to20130930" unitRef="U002" decimals="-3">-1622000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-11176000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20140101to20140930" unitRef="U002" decimals="-3">1026000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20130101to20130930" unitRef="U002" decimals="-3">-240000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Increase (Decrease) in Deferred Revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20130101to20130930" unitRef="U002" decimals="-3">278000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Deferred Revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20140101to20140930" unitRef="U002" decimals="-3">3416000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-4729000</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20130101to20130930" unitRef="U002" decimals="-3">1164000</us-gaap:IncreaseDecreaseInInventories>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20130101to20130930" unitRef="U002" decimals="-3">-4164000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-208000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20140101to20140930" unitRef="U002" decimals="-3">4447000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20130101to20130930" unitRef="U002" decimals="-3">6927000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20130101to20130930" unitRef="U002" decimals="-3">3532000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20140101to20140930" unitRef="U002" decimals="-3">10845000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20130701to20130930" unitRef="U001" decimals="0">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20130101to20130930" unitRef="U001" decimals="0">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20140701to20140930" unitRef="U001" decimals="0">8095304</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities-->
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c20140101to20140930" unitRef="U001" decimals="0">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20140701to20140930" unitRef="U001" decimals="0">954639</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20130701to20130930" unitRef="U001" decimals="0">742950</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20130101to20130930" unitRef="U001" decimals="0">375047</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20140101to20140930" unitRef="U001" decimals="0">623837</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Intangible assets, net-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20131231" unitRef="U002" decimals="-3">30148000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible assets, net-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20140930" unitRef="U002" decimals="-3">64464000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20140101to20140930" unitRef="U002" decimals="-3">7066000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20130101to20130930" unitRef="U002" decimals="-3">14000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20140701to20140930" unitRef="U002" decimals="-3">1810000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20130701to20130930" unitRef="U002" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest on Convertible Debt, Net of Tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20140101to20140930" unitRef="U002" decimals="-3">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Interest on Convertible Debt, Net of Tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20140701to20140930" unitRef="U002" decimals="-3">917000</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Interest on Convertible Debt, Net of Tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Interest on Convertible Debt, Net of Tax-->
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c20130701to20130930" unitRef="U002" decimals="-3">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <!--Inventory, Net-->
  <us-gaap:InventoryNet contextRef="c20131231" unitRef="U002" decimals="-3">14643000</us-gaap:InventoryNet>
  <!--Inventory, Net-->
  <us-gaap:InventoryNet contextRef="c20140930" unitRef="U002" decimals="-3">62533000</us-gaap:InventoryNet>
  <!--Inventory, Policy [Policy Text Block]-->
  <us-gaap:InventoryPolicyTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Inventories&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Inventories are stated at the lower of cost or market with cost being determined using a standard cost method, which approximates average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third party suppliers. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to expired inventory.&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;Costs of purchased inventories are recorded using weighted-average costing. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <!--Finished goods-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20131231" unitRef="U002" decimals="-3">2168000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Finished goods-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20140930" unitRef="U002" decimals="-3">15061000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Inventory Disclosure [Text Block]-->
  <us-gaap:InventoryDisclosureTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;5.&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Inventories consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,089&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,656&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Work-in-process&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;31,383&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;9,819&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,061&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,168&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total inventories&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;62,533&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;14,643&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <!--Raw materials and supplies-->
  <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c20140930" unitRef="U002" decimals="-3">16089000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
  <!--Raw materials and supplies-->
  <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c20131231" unitRef="U002" decimals="-3">2656000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
  <!--Step up adjustment to inventory-Cangene [Member]-->
  <us-gaap:InventoryNoncurrentFairValueDisclosure contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-5">6200000</us-gaap:InventoryNoncurrentFairValueDisclosure>
  <!--Work-in-process-->
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c20140930" unitRef="U002" decimals="-3">31383000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <!--Work-in-process-->
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c20131231" unitRef="U002" decimals="-3">9819000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20140701to20140930" unitRef="U002" decimals="-3">59000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20130701to20130930" unitRef="U002" decimals="-3">88000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20140101to20140930" unitRef="U002" decimals="-3">130000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20130101to20130930" unitRef="U002" decimals="-3">121000</us-gaap:InvestmentIncomeInterest>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20140930" unitRef="U002" decimals="-3">81417000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20131231" unitRef="U002" decimals="-3">56651000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20131231" unitRef="U002" decimals="-3">626630000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20140930" unitRef="U002" decimals="-3">869291000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20140930_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">19233000</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">19233000</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">16619000</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">16619000</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Financial and Nonfinancial Liabilities, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</us-gaap:LiabilitiesFairValueDisclosure>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20131231" unitRef="U002" decimals="-3">137465000</us-gaap:Liabilities>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20140930" unitRef="U002" decimals="-3">356153000</us-gaap:Liabilities>
  <!--Revenue from license fee-Morphosys [Member]-->
  <us-gaap:LicenseAndServicesRevenue contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="-5">15300000</us-gaap:LicenseAndServicesRevenue>
  <!--Line of Credit Facility, Maximum Borrowing Capacity-EBS BAML Term Loan [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c20140930_LongtermDebtTypeAxis_EbsBamlTermLoanMember" unitRef="U002" decimals="-6">125000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <!--Line of Credit Facility, Maximum Borrowing Capacity-Revolving Credit Loan dated December 2013, due in December 2018 [Member]-->
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c20140930_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member" unitRef="U002" decimals="-6">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <!--Long-term Debt, Excluding Current Maturities-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20140930" unitRef="U002" decimals="-3">251000000</us-gaap:LongTermDebtNoncurrent>
  <!--Long-term Debt, Excluding Current Maturities-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20131231" unitRef="U002" decimals="-3">62000000</us-gaap:LongTermDebtNoncurrent>
  <!--Noncontrolling Interest Disclosure [Text Block]-->
  <us-gaap:MinorityInterestDisclosureTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;9.&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Variable interest entities&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In July 2008, the Company entered into a collaboration with the University of Oxford ("Oxford") and certain Oxford researchers to advance a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). The Company liquidated OETC during the nine month period ending September 30, 2014. In addition, the Company recorded an adjustment related to noncontrolling interest of $453,000 due to the liquidation. This expense was recorded as selling, general and administrative expense within the Company's Biosciences segment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
  <!--Noncontrolling interest in subsidiaries-->
  <us-gaap:MinorityInterest contextRef="c20131231" unitRef="U002" decimals="-3">-453000</us-gaap:MinorityInterest>
  <!--Noncontrolling interest in subsidiaries-->
  <us-gaap:MinorityInterest contextRef="c20140930" unitRef="U002" decimals="-3">0</us-gaap:MinorityInterest>
  <!--Net income-->
  <us-gaap:NetIncomeLoss contextRef="c20130701to20130930" unitRef="U002" decimals="-3">13491000</us-gaap:NetIncomeLoss>
  <!--Net income-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130930" unitRef="U002" decimals="-3">15913000</us-gaap:NetIncomeLoss>
  <!--Net income-->
  <us-gaap:NetIncomeLoss contextRef="c20140701to20140930" unitRef="U002" decimals="-3">21832000</us-gaap:NetIncomeLoss>
  <!--Net income-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20140930" unitRef="U002" decimals="-3">6625000</us-gaap:NetIncomeLoss>
  <!--Net income-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20140930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">-6359000</us-gaap:NetIncomeLoss>
  <!--Net income-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">-2848000</us-gaap:NetIncomeLoss>
  <!--Net income-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130930_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">56780000</us-gaap:NetIncomeLoss>
  <!--Net income-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130701to20130930_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">27175000</us-gaap:NetIncomeLoss>
  <!--Net income-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140701to20140930_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">-496000</us-gaap:NetIncomeLoss>
  <!--Net income-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20140930_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">-43321000</us-gaap:NetIncomeLoss>
  <!--Net income-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130930_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">-38019000</us-gaap:NetIncomeLoss>
  <!--Net income-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20140930_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">56305000</us-gaap:NetIncomeLoss>
  <!--Net income-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140701to20140930_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">25182000</us-gaap:NetIncomeLoss>
  <!--Net income-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130701to20130930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">-1193000</us-gaap:NetIncomeLoss>
  <!--Net income-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130701to20130930_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">-12491000</us-gaap:NetIncomeLoss>
  <!--Net income-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20140701to20140930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">-2854000</us-gaap:NetIncomeLoss>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-192788000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20130101to20130930" unitRef="U002" decimals="-3">-58540000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20140101to20140930" unitRef="U002" decimals="-3">195185000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20130101to20130930" unitRef="U002" decimals="-3">1102000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20130101to20130930" unitRef="U002" decimals="-3">88327000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20140101to20140930" unitRef="U002" decimals="-3">60497000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Income (Loss) Attributable to Noncontrolling Interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20140101to20140930" unitRef="U002" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net Income (Loss) Attributable to Noncontrolling Interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20140701to20140930" unitRef="U002" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net Income (Loss) Attributable to Noncontrolling Interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130701to20130930" unitRef="U002" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net Income (Loss) Attributable to Noncontrolling Interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130101to20130930" unitRef="U002" decimals="-3">-871000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20140701to20140930" unitRef="U002" decimals="-3">-1331000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20130701to20130930" unitRef="U002" decimals="-3">146000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-4682000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20130101to20130930" unitRef="U002" decimals="-3">200000</us-gaap:NonoperatingIncomeExpense>
  <!--Number of business segments-->
  <us-gaap:NumberOfReportableSegments contextRef="c20140101to20140930" unitRef="U008" decimals="INF">2</us-gaap:NumberOfReportableSegments>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130701to20130930" unitRef="U002" decimals="-3">18147000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140101to20140930" unitRef="U002" decimals="-3">13436000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130101to20130930" unitRef="U002" decimals="-3">19509000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140701to20140930" unitRef="U002" decimals="-3">31032000</us-gaap:OperatingIncomeLoss>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c20130101to20130930_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c20140101to20140930_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax-Biosciences [Member]-Selling, General and Administrative Expenses [Member]-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c20140101to20140930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="0">453000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20130101to20130930" unitRef="U002" decimals="-3">627000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20130701to20130930" unitRef="U002" decimals="-3">11000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-345000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20140701to20140930" unitRef="U002" decimals="-3">-559000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20131231" unitRef="U002" decimals="-3">3373000</us-gaap:OtherAssetsNoncurrent>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20140930" unitRef="U002" decimals="-3">8340000</us-gaap:OtherAssetsNoncurrent>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-541000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20130101to20130930" unitRef="U002" decimals="-3">19000</us-gaap:OtherNoncashIncomeExpense>
  <!--Non-cash development expenses from joint venture-->
  <us-gaap:OtherNoncashExpense contextRef="c20130101to20130930" unitRef="U002" decimals="-3">-348000</us-gaap:OtherNoncashExpense>
  <!--Non-cash development expenses from joint venture-->
  <us-gaap:OtherNoncashExpense contextRef="c20140101to20140930" unitRef="U002" decimals="-3">0</us-gaap:OtherNoncashExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20130101to20130930" unitRef="U002" decimals="-3">93000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20140701to20140930" unitRef="U002" decimals="-3">420000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20130701to20130930" unitRef="U002" decimals="-3">58000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20140101to20140930" unitRef="U002" decimals="-3">2254000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20140930" unitRef="U002" decimals="-3">1176000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20131231" unitRef="U002" decimals="-3">2117000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Payments to Acquire Businesses and Interest in Affiliates-->
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="c20140101to20140930" unitRef="U002" decimals="-3">0</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <!--Payments to Acquire Businesses and Interest in Affiliates-->
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="c20130101to20130930" unitRef="U002" decimals="-3">24120000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <!--Payments to Acquire Businesses, Net of Cash Acquired-->
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c20140101to20140930" unitRef="U002" decimals="-3">178167000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <!--Payments to Acquire Businesses, Net of Cash Acquired-->
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <!--Payments to Acquire Businesses, Gross-HPPD [Member]-->
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c20130731to20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">25873000</us-gaap:PaymentsToAcquireBusinessesGross>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20130101to20130930" unitRef="U002" decimals="-3">34420000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20140930" unitRef="U002" decimals="-3">14621000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20140930" unitRef="U003" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20131231" unitRef="U003" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively-->
  <us-gaap:PreferredStockValue contextRef="c20140930" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively-->
  <us-gaap:PreferredStockValue contextRef="c20131231" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20140930" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20131231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20140930" unitRef="U001" decimals="0">15000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20131231" unitRef="U001" decimals="0">15000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20140930" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20131231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20131231" unitRef="U002" decimals="-3">12896000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20140930" unitRef="U002" decimals="-3">26477000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Proceeds from Convertible Debt-->
  <us-gaap:ProceedsFromConvertibleDebt contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
  <!--Proceeds from Convertible Debt-->
  <us-gaap:ProceedsFromConvertibleDebt contextRef="c20140101to20140930" unitRef="U002" decimals="-3">241654000</us-gaap:ProceedsFromConvertibleDebt>
  <!--Proceeds from other long-term debt obligations-->
  <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
  <!--Proceeds from other long-term debt obligations-->
  <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c20140101to20140930" unitRef="U002" decimals="-3">1000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
  <!--Issuance of common stock subject to exercise of stock options-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20130101to20130930" unitRef="U002" decimals="-3">2505000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Issuance of common stock subject to exercise of stock options-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20140101to20140930" unitRef="U002" decimals="-3">10656000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ProfitLoss contextRef="c20130701to20130930" unitRef="U002" decimals="-3">13491000</us-gaap:ProfitLoss>
  <!--Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ProfitLoss contextRef="c20140701to20140930" unitRef="U002" decimals="-3">21832000</us-gaap:ProfitLoss>
  <!--Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ProfitLoss contextRef="c20140101to20140930" unitRef="U002" decimals="-3">6625000</us-gaap:ProfitLoss>
  <!--Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ProfitLoss contextRef="c20130101to20130930" unitRef="U002" decimals="-3">15042000</us-gaap:ProfitLoss>
  <!--Property, plant and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20140930" unitRef="U002" decimals="-3">304211000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, plant and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20131231" unitRef="U002" decimals="-3">264240000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20130101to20130930" unitRef="U002" decimals="-3">3352000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20140101to20140930" unitRef="U002" decimals="-3">62000000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Repayments of Long-term Debt-Revolving Credit Loan dated December 2013, due in December 2018 [Member]-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20140101to20140930_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member" unitRef="U002" decimals="-5">62000000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20140930" unitRef="U002" decimals="-3">111864000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130701to20130930" unitRef="U002" decimals="-3">28937000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130101to20130930" unitRef="U002" decimals="-3">89939000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140701to20140930" unitRef="U002" decimals="-3">44207000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Restructuring Charges-->
  <us-gaap:RestructuringCharges contextRef="c20150101to20150630" unitRef="U002" decimals="-6">5000000</us-gaap:RestructuringCharges>
  <!--Retained earnings-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20131231" unitRef="U002" decimals="-3">251528000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Retained earnings-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20140930" unitRef="U002" decimals="-3">258152000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Revenue recognition-->
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Revenue recognition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company recognizes revenues from product sales if four basic criteria have been met:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;there is persuasive evidence of an arrangement;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;delivery has occurred or title has passed to the Company's customer;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;the fee is fixed or determinable; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;collectability is reasonably assured.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;All revenues from product sales are recorded net of applicable allowances for sales rebates, special promotional programs, and discounts. The Company estimates allowances for revenue reducing obligations using a combination of information received from third parties including market data, inventory reports from major wholesalers, historical information and analysis. These estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates and reflect other limitations. Provisions for estimated rebates and other allowances, such as discounts and promotional and other credits, are estimated based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and contract terms, and actual discounts offered.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company markets and sells its Biosciences products through commercial wholesalers (direct customers) who purchase the products at a price referred to as the wholesale acquisition cost ("WAC"). Additionally, the Company enters into agreements with indirect customers for a contracted price that is less than the WAC. The indirect customers, such as group-purchasing organizations, physician practice-management groups and hospitals, purchase the Company's products from the wholesalers. Under these agreements with wholesalers, the Company guarantees to credit them for the difference between the WAC and the indirect customers' contracted price. This credit is referred to as a chargeback. Adjustments to the Company's chargeback provisions are made periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company makes subjective judgements primarily based on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or as an adjustment to past sales, or both.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's relative selling price and is recognized when the appropriate revenue recognition criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Revenue associated with non-refundable upfront license fees that can be treated as a single unit of accounting are recognized when all ongoing obligations have been delivered. Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting are deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company would recognize such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract..&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company generates revenues from its August 2014 collaboration agreement with MorphoSys. The collaboration provides for sharing of development and clinical costs, with the Company responsible for 36% of such costs and MorphoSys responsible for the remainder. In the event the Company's share of the total cost for a given quarter exceeds 36% of the total costs for the project, the Company records a net receivable in its financial statements equal to the difference between the Company's costs and 36% of the total costs for the period, and reduces research and development expense in this amount. If the Company's share of the cost for the quarterly period is less than 36% of the total costs for the project, the Company records a net payable in its financial statements equal to the difference between the Company's costs and 36% of the total costs, and records additional research and development expenses in this amount.&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <!--External revenue-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20130701to20130930_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">89102000</us-gaap:Revenues>
  <!--External revenue-->
  <us-gaap:Revenues contextRef="c20140701to20140930" unitRef="U002" decimals="-3">137954000</us-gaap:Revenues>
  <!--External revenue-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20140930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20140701to20140930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-->
  <us-gaap:Revenues contextRef="c20140101to20140930" unitRef="U002" decimals="-3">302163000</us-gaap:Revenues>
  <!--External revenue-->
  <us-gaap:Revenues contextRef="c20130101to20130930" unitRef="U002" decimals="-3">214638000</us-gaap:Revenues>
  <!--External revenue-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20130701to20130930_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20140930_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">59001000</us-gaap:Revenues>
  <!--External revenue-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20140101to20140930_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">243162000</us-gaap:Revenues>
  <!--External revenue-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20130930_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">213663000</us-gaap:Revenues>
  <!--External revenue-->
  <us-gaap:Revenues contextRef="c20130701to20130930" unitRef="U002" decimals="-3">89102000</us-gaap:Revenues>
  <!--External revenue-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20130701to20130930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20130930_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">975000</us-gaap:Revenues>
  <!--External revenue-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20140701to20140930_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">104130000</us-gaap:Revenues>
  <!--External revenue-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20130930_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20140701to20140930_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">33824000</us-gaap:Revenues>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value-Stock Options Member [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember" unitRef="U002" decimals="0">9446930</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20130701to20130930" unitRef="U002" decimals="-3">76297000</us-gaap:SalesRevenueGoodsNet>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20140701to20140930" unitRef="U002" decimals="-3">84457000</us-gaap:SalesRevenueGoodsNet>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20140101to20140930" unitRef="U002" decimals="-3">198493000</us-gaap:SalesRevenueGoodsNet>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20130101to20130930" unitRef="U002" decimals="-3">172252000</us-gaap:SalesRevenueGoodsNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20140701to20140930" unitRef="U002" decimals="-3">137954000</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20130101to20130930" unitRef="U002" decimals="-3">214638000</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20140101to20140930" unitRef="U002" decimals="-3">302163000</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20130701to20130930" unitRef="U002" decimals="-3">89102000</us-gaap:SalesRevenueNet>
  <!--Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]-->
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The total purchase price is summarized below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Amount of cash paid to Bracco Diagnostics Inc.&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;25,873&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Fair value of contingent purchase consideration at date of acquisition&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,232&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;42,105&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <!--Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis-->
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&amp;#160;The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;154,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;154,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;154,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;154,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,233&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #ffffff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; background-color: #cceeff; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,701&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <!--Schedule of Business Acquisitions, by Acquisition [Table Text Block]-->
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at February 21, 2014.&amp;#160;As of the date of this filing, the valuation of acquired intangible assets, deferred taxes and other fair value adjustments are not complete as the Company is obtaining and analyzing additional information related to the aforementioned items. As such, the purchase price allocation is subject to change.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;February 21, 2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Fair value of tangible assets acquired and liabilities assumed:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Cash&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;43,631&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Accounts receivable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,649&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Inventory (i)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;52,619&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Prepaid expenses and other assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;40,264&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Deferred taxes, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;18,371&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Income tax receivable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,940&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(22,918&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Provision for chargebacks&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(2,447&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Contingent purchase consideration&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,089&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(6,378&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total fair value of tangible assets acquired and liabilities assumed&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;147,017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Acquired in-process research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,500&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Acquired intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;40,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;25,883&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;221,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(i) Acquired inventory reflects a $6.2 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $6.2 million step-up is estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on expected inventory turnover, which will increase cost of product sales and contract manufacturing during such period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;During the three months ended September 30, 2014 the Company updated its fair value determination for contingent purchase consideration and the provision for chargebacks resulting in a reduction to goodwill of $5.9 million and a reduction to contingent purchase consideration and the provision of chargebacks.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
  <!--Option Award Activity-->
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;As of September 30, 2014, the Company had two stock-based employee compensation plans, the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan") (together, the "Emergent Plans").&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;On May 22, 2014, the Company's shareholders approved an amendment to the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 4,000,000. As part of this amendment, awards of restricted stock units granted after May 22, 2014 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 2.3 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 1,000,000.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following is a summary of stock option award activity under the Emergent Plans:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2006 Plan&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2004 Plan&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: ''Times New Roman'', Times, serif; margin-left: 9pt; font-size: 10pt;"&gt;Outstanding at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,633,146&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;17.01&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;53,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;23,148,738&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.55pt; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;1,116,721&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;27.49&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.55pt; font-size: 10pt;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(663,256&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16.66&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9.35pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.55pt; font-size: 10pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(92,549&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19.69&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: ''Times New Roman'', Times, serif; margin-left: 9pt; font-size: 10pt;"&gt;Outstanding at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,994,062&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19.94&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;53,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;14,289,421&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 40%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: -9pt; font-family: ''Times New Roman'', Times, serif; margin-left: 9pt; font-size: 10pt;"&gt;Exercisable at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,086,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;17.76&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;53,156&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8.86&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;9,446,930&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <!--Intangible Assets-->
  <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 3pt; font-size: 10pt;"&gt;Intangible assets consist of the following:&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Corporate&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Marketed&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Licensed&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Contract&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;RSDL&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Agreement&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Tradename&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Products&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cost basis&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;28,621&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;32,099&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;20,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,600&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;40,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;28,621&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,478&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;20,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,600&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;72,499&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,468&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(483&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 15px;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(2,640&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(870&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(338&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(285&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,026&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(423&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(6,084&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(4,108&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,353&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(338&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(502&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(285&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,026&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(423&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(8,035&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 20%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 7%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 20%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net book value at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;24,513&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,125&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,462&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;7,798&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19,374&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,177&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 7%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;64,464&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
  <!--Restricted Stock Units Activity-->
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following is a summary of restricted stock unit award activity under the 2006 Plan:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted-Average Grant Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Outstanding at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;789,951&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16.53&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;18,246,611&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;558,362&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;27.49&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Vested&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(345,072&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;17.76&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(44,275&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;19.66&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Outstanding at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;958,966&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;22.32&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;20,435,565&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <!--Summary of Basic and Diluted Net Income per Share-->
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For the three and nine month periods ended September 30, 2014 and 2013, basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For the three and nine month periods ended September 30, 2014, diluted earnings per share is computed using the if-converted method by dividing the adjusted net income by the weighted average number of shares of common stock outstanding during the period. The adjusted net income is adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the Company's Notes. The weighted average number of shares-diluted is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For the three and nine months ended September 30, 2013, diluted earnings per share is computed using the treasury method by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The following table presents the calculation of basic and diluted net income per share:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Nine Months Ended September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands, except share and per share data)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;21,832&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;13,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;6,625&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,913&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Interest expense applicable to convertible debt, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;917&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Amortization of debt issuance costs, net of tax&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;203&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Adjusted net income&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;22,952&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;13,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;6,625&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,913&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Weighted-average number of shares&amp;#8212;basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,507,220&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;36,272,579&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,261,357&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;36,129,183&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Dilutive securities&amp;#8212;equity awards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;954,639&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;742,950&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;623,837&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;375,047&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Dilutive securities&amp;#8212;convertible debt&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,095,304&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Weighted-average number of shares&amp;#8212;diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;46,557,163&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,015,529&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;37,885,194&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;36,504,230&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Income per share-basic&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.58&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.37&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.18&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.44&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Income per share-diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.49&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.36&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.17&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;0.44&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <!--Schedule of Inventory, Current [Table Text Block]-->
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Inventories consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;September 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,089&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,656&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Work-in-process&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;31,383&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;9,819&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,061&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,168&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total inventories&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;62,533&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;14,643&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <!--Schedule of Goodwill [Table Text Block]-->
  <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 3pt; font-size: 10pt;"&gt;The following table is a summary of changes in goodwill:&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/font&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cost basis&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at December 31, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;13,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;27,347&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Balance at September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;41,301&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
  <!--Fair Value of Intangible Assets-->
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: middle;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Period&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;( in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;in years&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Corporate Trade Name&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;2,800&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Marketed Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;10.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Licensed Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;3,300&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;7.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Biodefense Products&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;20,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;12.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Contract Manufacturing&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;5,600&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;8.0&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 76%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total identified intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;40,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
  <!--Schedule of Segment Reporting Information, by Segment [Table Text Block]-->
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Biodefense division &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;is a specialty biopharmaceutical business focused on countermeasures that address Chemical, Biological, Radiological and Nuclear threats and consists of two business units: vaccines and therapeutics, and medical devices.&lt;/font&gt; Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax&amp;#174; (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;is directed to commercial opportunities and primarily targets hematology/oncology, transplantation and infectious diseases&lt;/font&gt;, and consists of three business units, therapeutics, vaccines and contract manufacturing. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="14" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Reportable Segments&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Biosciences&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;All Other&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;104,130&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;33,824&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;137,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;25,182&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(496&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(2,854&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;21,832&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;89,102&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;89,102&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;27,175&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(12,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,193&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;13,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Nine Months Ended September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;243,162&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;59,001&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;302,163&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;56,305&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(43,321&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(6,359&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;6,625&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Nine Months Ended September 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;213,663&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;975&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;214,638&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;56,780&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(38,019&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(2,848&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,913&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <!--Segment Reporting Disclosure [Text Block]-->
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;11. Segment information&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is provided to and resources are allocated by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different manufacturing and development processes, along with having separate and distinct sales and marketing processes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Biodefense division &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;is a specialty biopharmaceutical business focused on countermeasures that address Chemical, Biological, Radiological and Nuclear threats and consists of two business units: vaccines and therapeutics, and medical devices.&lt;/font&gt; Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax&amp;#174; (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division &lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;is directed to commercial opportunities and primarily targets hematology/oncology, transplantation and infectious diseases&lt;/font&gt;, and consists of three business units, therapeutics, vaccines and contract manufacturing. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="14" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Reportable Segments&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Biosciences&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;All Other&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;104,130&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;33,824&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;137,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;25,182&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(496&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(2,854&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;21,832&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;89,102&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;89,102&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 8pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;27,175&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(12,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(1,193&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;13,491&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Nine Months Ended September 30, 2014&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;243,162&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;59,001&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;302,163&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;56,305&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(43,321&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(6,359&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;6,625&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Nine Months Ended September 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;External revenue&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;213,663&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;975&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;214,638&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;56,780&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(38,019&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;(2,848&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;15,913&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20130101to20130930" unitRef="U002" decimals="-3">62484000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20140101to20140930" unitRef="U002" decimals="-3">90936000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20130701to20130930" unitRef="U002" decimals="-3">21955000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20140701to20140930" unitRef="U002" decimals="-3">30292000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Granted (in shares)-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c20140101to20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">558362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c20140101to20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">27.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Granted (in dollars per share)-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Granted (in dollars per share)-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">27.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c20131231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">789951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">958966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20130101to20130930" unitRef="U002" decimals="-3">8459000</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20140101to20140930" unitRef="U002" decimals="-3">9454000</us-gaap:ShareBasedCompensation>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c20140101to20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">345072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c20131231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">16.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">22.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="c20140101to20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">19.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c20140101to20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">44275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <!--Exercised (in dollars per share)-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <!--Exercised (in dollars per share)-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">16.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">1116721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">8.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="c20140101to20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">53156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">2086114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Forfeited (in dollars per share)-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">19.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Forfeited (in dollars per share)-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">92549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20131231_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">17.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20131231_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">8.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">19.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">8.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20131231_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">3633146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20131231_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">53156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">3994062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">53156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20131231_AwardTypeAxis_StockOptionsMemberMember" unitRef="U002" decimals="0">23148738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Stock Options Member [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember" unitRef="U002" decimals="0">14289421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Significant Accounting Policies [Text Block]-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;1.&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Summary of significant accounting policies&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Basis of presentation and consolidation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 3pt; font-size: 10pt;"&gt;In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of September 30, 2014; the results of operations and comprehensive income for the three and nine months ended September 30, 2014 and 2013; and cash flows for the nine months ended September 30, 2014 and 2013. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-top: 3pt; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; margin-bottom: 3pt; font-size: 10pt;"&gt;There have been no significant changes to the Company's summary of significant accounting policies, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC, during the nine months ended September 30, 2014, except for additions to the Company's accounting policies for revenue recognition and inventories related to the Cangene Corporation ("Cangene") acquisition (Note 2) and revenue recognition for the MorphoSys AG ("MorphoSys") collaboration (Note 4).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Revenue recognition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company recognizes revenues from product sales if four basic criteria have been met:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;there is persuasive evidence of an arrangement;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;delivery has occurred or title has passed to the Company's customer;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;the fee is fixed or determinable; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;collectability is reasonably assured.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;All revenues from product sales are recorded net of applicable allowances for sales rebates, special promotional programs, and discounts. The Company estimates allowances for revenue reducing obligations using a combination of information received from third parties including market data, inventory reports from major wholesalers, historical information and analysis. These estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates and reflect other limitations. Provisions for estimated rebates and other allowances, such as discounts and promotional and other credits, are estimated based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and contract terms, and actual discounts offered.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company markets and sells its Biosciences products through commercial wholesalers (direct customers) who purchase the products at a price referred to as the wholesale acquisition cost ("WAC"). Additionally, the Company enters into agreements with indirect customers for a contracted price that is less than the WAC. The indirect customers, such as group-purchasing organizations, physician practice-management groups and hospitals, purchase the Company's products from the wholesalers. Under these agreements with wholesalers, the Company guarantees to credit them for the difference between the WAC and the indirect customers' contracted price. This credit is referred to as a chargeback. Adjustments to the Company's chargeback provisions are made periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company makes subjective judgements primarily based on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or as an adjustment to past sales, or both.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's relative selling price and is recognized when the appropriate revenue recognition criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Revenue associated with non-refundable upfront license fees that can be treated as a single unit of accounting are recognized when all ongoing obligations have been delivered. Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting are deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company would recognize such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract..&lt;/div&gt;&lt;div style="margin-top: 3pt; margin-bottom: 3pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The Company generates revenues from its August 2014 collaboration agreement with MorphoSys. The collaboration provides for sharing of development and clinical costs, with the Company responsible for 36% of such costs and MorphoSys responsible for the remainder. In the event the Company's share of the total cost for a given quarter exceeds 36% of the total costs for the project, the Company records a net receivable in its financial statements equal to the difference between the Company's costs and 36% of the total costs for the period, and reduces research and development expense in this amount. If the Company's share of the cost for the quarterly period is less than 36% of the total costs for the project, the Company records a net payable in its financial statements equal to the difference between the Company's costs and 36% of the total costs, and records additional research and development expenses in this amount.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Inventories&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Inventories are stated at the lower of cost or market with cost being determined using a standard cost method, which approximates average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third party suppliers. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to expired inventory.&lt;font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;Costs of purchased inventories are recorded using weighted-average costing. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period-Stock Options Member [Member]-Emergent BioSolutions Employee Stock Option Plan [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period-Stock Options Member [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20140101to20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">663256</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20140930" unitRef="U002" decimals="-3">513138000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20131231" unitRef="U002" decimals="-3">489618000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20131231" unitRef="U002" decimals="-3">489165000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20140930" unitRef="U002" decimals="-3">513138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Subsequent Event-->
  <us-gaap:SubsequentEventsTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Note 12. Subsequent Events&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;In October 2014, the Company announced a plan to cease its product development activities in Munich, Germany, close its Princeton, New Jersey sales and marketing office, and sell its Henlow Bay development/manufacturing facility in Winnipeg, Canada. The key drivers for this restructuring include the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;Reprioritization of the Company's product development portfolio;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;Relocation of manufacturing development work for the Company's platform products;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;Centralization of laboratory work; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="width: 18pt; font-family: Wingdings; font-size: 10pt; vertical-align: top; align: right;"&gt;&amp;#167;&lt;/td&gt;&lt;td style="text-align: justify; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top;"&gt;Centralization of sales and marketing activities.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The restructuring entails a headcount reduction, sale of facilities and equipment, and the potential impairment of leasehold improvements and certain other equipment. The Company expects to complete this restructuring in the first half of 2015, and estimates that the total cost of the restructuring will be up to $5.0 million.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <!--Treasury stock (in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20140930" unitRef="U001" decimals="0">412953</us-gaap:TreasuryStockShares>
  <!--Treasury stock (in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20131231" unitRef="U001" decimals="0">412953</us-gaap:TreasuryStockShares>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20131231" unitRef="U002" decimals="-3">6119000</us-gaap:TreasuryStockValue>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20140930" unitRef="U002" decimals="-3">6119000</us-gaap:TreasuryStockValue>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20140101to20140930" unitRef="U001" decimals="0">37261357</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20140701to20140930" unitRef="U001" decimals="0">37507220</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20130101to20130930" unitRef="U001" decimals="0">36129183</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic (in shares)-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20130701to20130930" unitRef="U001" decimals="0">36272579</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20140701to20140930" unitRef="U001" decimals="0">46557163</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20130701to20130930" unitRef="U001" decimals="0">37015529</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20130101to20130930" unitRef="U001" decimals="0">36504230</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20140101to20140930" unitRef="U001" decimals="0">37885194</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Basic criteria for revenue recognition-->
  <ebs:BasicCriteriaForRevenueRecognition contextRef="c20140101to20140930" unitRef="U004" decimals="INF">4</ebs:BasicCriteriaForRevenueRecognition>
  <!--Contingent Consideration Percentage Of Net Sales-Minimum [Member]-HPPD [Member]-->
  <ebs:ContingentConsiderationPercentageOfNetSales contextRef="c20130801_BusinessAcquisitionAxis_HppdMember_RangeAxis_MinimumMember" unitRef="U005" decimals="INF">0.05</ebs:ContingentConsiderationPercentageOfNetSales>
  <!--Contingent Consideration Percentage Of Net Sales-Maximum [Member]-HPPD [Member]-->
  <ebs:ContingentConsiderationPercentageOfNetSales contextRef="c20130801_BusinessAcquisitionAxis_HppdMember_RangeAxis_MaximumMember" unitRef="U005" decimals="INF">0.1</ebs:ContingentConsiderationPercentageOfNetSales>
  <!--us-gaap_ Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Accrued Liabilities-Cangene [Member]-->
  <ebs:UsGaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAccruedLiabilities contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">22918000</ebs:UsGaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAccruedLiabilities>
  <!--us-gaap_ Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Accrued Liabilities-HPPD [Member]-->
  <ebs:UsGaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAccruedLiabilities contextRef="c20130801_BusinessAcquisitionAxis_HppdMember" unitRef="U002" decimals="-3">1464000</ebs:UsGaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAccruedLiabilities>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Provision for Chargebacks-Cangene [Member]-->
  <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesProvisionForChargebacks contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">2447000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesProvisionForChargebacks>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Royalty Provision-Cangene [Member]-->
  <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRoyaltyProvision contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">1089000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRoyaltyProvision>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Income tax receivable-Cangene [Member]-->
  <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxReceivable contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">2940000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxReceivable>
  <!--Amortization period of step up adjustment-Cangene [Member]-->
  <ebs:AmortizationPeriodOfStepUpAdjustment contextRef="c20140101to20140930_BusinessAcquisitionAxis_CangeneMember">P5Y</ebs:AmortizationPeriodOfStepUpAdjustment>
  <!--Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, In-process research and development-Cangene [Member]-->
  <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment contextRef="c20140221_BusinessAcquisitionAxis_CangeneMember" unitRef="U002" decimals="-3">8500000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment>
  <!--Purchase Price HPPD [Table Text Block]-->
  <ebs:PurchasePriceHppdTableTextBlock contextRef="c20140101to20140930">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;The total purchase price is summarized below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Amount of cash paid to Bracco Diagnostics Inc.&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;25,873&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Fair value of contingent purchase consideration at date of acquisition&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;16,232&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 88%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;Total purchase price&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"&gt;42,105&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</ebs:PurchasePriceHppdTableTextBlock>
  <!--Change In Fair Value Of Contingent Obligations-->
  <ebs:ChangeInFairValueOfContingentObligations contextRef="c20140701to20140930" unitRef="U002" decimals="-5">1600000</ebs:ChangeInFairValueOfContingentObligations>
  <!--Change In Fair Value Of Contingent Obligations-->
  <ebs:ChangeInFairValueOfContingentObligations contextRef="c20140101to20140930" unitRef="U002" decimals="-5">3200000</ebs:ChangeInFairValueOfContingentObligations>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">19233000</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20140930_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">19233000</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20131231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">16619000</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20140930_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Measurements, Recurring [Member]-Fair Value, Inputs, Level 1 [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">0</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Contingent Value Rights, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-Fair Value, Measurements, Recurring [Member]-->
  <ebs:ContingentValueRightsFairValueDisclosure contextRef="c20131231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U002" decimals="-3">16619000</ebs:ContingentValueRightsFairValueDisclosure>
  <!--Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues-->
  <ebs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssues contextRef="c20140101to20140930" unitRef="U002" decimals="-3">1089000</ebs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssues>
  <!--Share Based Compensation Arrangement, Equity Instruments other than Options, Outstanding, Aggregate Intrinsic value-Restricted Stock Units (RSUs) [Member]-->
  <ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue contextRef="c20131231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0">18246611</ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue>
  <!--Share Based Compensation Arrangement, Equity Instruments other than Options, Outstanding, Aggregate Intrinsic value-Restricted Stock Units (RSUs) [Member]-->
  <ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue contextRef="c20140930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0">20435565</ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue>
  <!--Restricted stock unit conversion ratio-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-Stock Options Member [Member]-->
  <ebs:RestrictedStockUnitConversionRatio contextRef="c20140930_AwardTypeAxis_StockOptionsMemberMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="2">2.30</ebs:RestrictedStockUnitConversionRatio>
  <!--Contract manufacturing-->
  <ebs:ContractManufacturing contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</ebs:ContractManufacturing>
  <!--Contract manufacturing-->
  <ebs:ContractManufacturing contextRef="c20140701to20140930" unitRef="U002" decimals="-3">9433000</ebs:ContractManufacturing>
  <!--Contract manufacturing-->
  <ebs:ContractManufacturing contextRef="c20140101to20140930" unitRef="U002" decimals="-3">21346000</ebs:ContractManufacturing>
  <!--Contract manufacturing-->
  <ebs:ContractManufacturing contextRef="c20130701to20130930" unitRef="U002" decimals="-3">0</ebs:ContractManufacturing>
  <!--Number of business units-->
  <ebs:NumberOfBusinessUnits contextRef="c20140101to20140930" unitRef="U009" decimals="INF">3</ebs:NumberOfBusinessUnits>
  <!--Provision for chargebacks, charged to earnings-->
  <ebs:ProvisionForChargebacksChargedToEarnings contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</ebs:ProvisionForChargebacksChargedToEarnings>
  <!--Provision for chargebacks, charged to earnings-->
  <ebs:ProvisionForChargebacksChargedToEarnings contextRef="c20140101to20140930" unitRef="U002" decimals="-3">-308000</ebs:ProvisionForChargebacksChargedToEarnings>
  <!--Write off of bank fees-->
  <ebs:WriteOffOfBankFees contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</ebs:WriteOffOfBankFees>
  <!--Write off of bank fees-->
  <ebs:WriteOffOfBankFees contextRef="c20140101to20140930" unitRef="U002" decimals="-3">1831000</ebs:WriteOffOfBankFees>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20130101to20130930" unitRef="U002" decimals="-3">0</ebs:ContingentValueRightPayment>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20140101to20140930" unitRef="U002" decimals="-3">1691000</ebs:ContingentValueRightPayment>
  <!--Change In Fair Value Of Contingent Purchase Consideration-->
  <ebs:ChangeInFairValueOfContingentPurchaseConsideration contextRef="c20140101to20140930" unitRef="U002" decimals="-3">3216000</ebs:ChangeInFairValueOfContingentPurchaseConsideration>
  <!--Change In Fair Value Of Contingent Purchase Consideration-->
  <ebs:ChangeInFairValueOfContingentPurchaseConsideration contextRef="c20130101to20130930" unitRef="U002" decimals="-3">349000</ebs:ChangeInFairValueOfContingentPurchaseConsideration>
  <!--Provision for chargebacks-->
  <ebs:ProvisionForChargebacks contextRef="c20140930" unitRef="U002" decimals="-3">2139000</ebs:ProvisionForChargebacks>
  <!--Provision for chargebacks-->
  <ebs:ProvisionForChargebacks contextRef="c20131231" unitRef="U002" decimals="-3">0</ebs:ProvisionForChargebacks>
  <!--Contingent Purchase Consideration Net Of Current Portion-->
  <ebs:ContingentPurchaseConsiderationNetOfCurrentPortion contextRef="c20140930" unitRef="U002" decimals="-3">16745000</ebs:ContingentPurchaseConsiderationNetOfCurrentPortion>
  <!--Contingent Purchase Consideration Net Of Current Portion-->
  <ebs:ContingentPurchaseConsiderationNetOfCurrentPortion contextRef="c20131231" unitRef="U002" decimals="-3">15278000</ebs:ContingentPurchaseConsiderationNetOfCurrentPortion>
  <!--Contingent Purchase Consideration Current Portion-->
  <ebs:ContingentPurchaseConsiderationCurrentPortion contextRef="c20131231" unitRef="U002" decimals="-3">1341000</ebs:ContingentPurchaseConsiderationCurrentPortion>
  <!--Contingent Purchase Consideration Current Portion-->
  <ebs:ContingentPurchaseConsiderationCurrentPortion contextRef="c20140930" unitRef="U002" decimals="-3">2488000</ebs:ContingentPurchaseConsiderationCurrentPortion>
  <!--In process research and development-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20131231" unitRef="U002" decimals="-3">41800000</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20140930" unitRef="U002" decimals="-3">50300000</ebs:InProcessResearchAndDevelopment>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20140701to20140930" unitRef="U002" decimals="-3">22952000</ebs:AdjustedNetLoss>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20130101to20130930" unitRef="U002" decimals="-3">15913000</ebs:AdjustedNetLoss>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20140101to20140930" unitRef="U002" decimals="-3">6625000</ebs:AdjustedNetLoss>
  <!--Adjusted net loss-->
  <ebs:AdjustedNetLoss contextRef="c20130701to20130930" unitRef="U002" decimals="-3">13491000</ebs:AdjustedNetLoss>
  <!--Debt Instrument, Number of Equity Instruments-Convertible Senior Notes Due 2021 [Member]-->
  <ebs:DebtInstrumentNumberOfEquityInstruments contextRef="c20140101to20140129_LongtermDebtTypeAxis_ConvertibleSeniorNotesDue2021Member" unitRef="U001" decimals="4">30.8821</ebs:DebtInstrumentNumberOfEquityInstruments>
  <!--Proceeds From Borrowings On Long Term Indebtness And Line Of Credit-Revolving Credit Loan dated December 2013, due in December 2018 [Member]-->
  <ebs:ProceedsFromBorrowingsOnLongTermIndebtnessAndLineOfCredit contextRef="c20130101to20131231_LongtermDebtTypeAxis_RevolvingCreditLoanDatedDecember2013DueInDecember2018Member" unitRef="U002" decimals="-5">62000000</ebs:ProceedsFromBorrowingsOnLongTermIndebtnessAndLineOfCredit>
  <!--Debt instrument covenant, minimum cash and liquid investments balance-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantMinimumCashAndLiquidInvestmentsBalance contextRef="c20140930_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U002" decimals="-6">50000000</ebs:DebtInstrumentCovenantMinimumCashAndLiquidInvestmentsBalance>
  <!--Debt Instrument, covenant, debt coverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantDebtCoverageRatio contextRef="c20140101to20140930_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U005" decimals="INF">2.50</ebs:DebtInstrumentCovenantDebtCoverageRatio>
  <!--Number of lending institutions-Credit Agreement [Member]-->
  <ebs:NumberOfLendingInstitutions contextRef="c20140701to20140930_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U007" decimals="INF">3</ebs:NumberOfLendingInstitutions>
  <!--Debt Instrument, covenant, senior leverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantSeniorLeverageRatio contextRef="c20140101to20140930_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U005" decimals="INF">2.00</ebs:DebtInstrumentCovenantSeniorLeverageRatio>
  <!--Debt Instrument, covenant, leverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantLeverageRatio contextRef="c20140101to20140930_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U005" decimals="INF">4.00</ebs:DebtInstrumentCovenantLeverageRatio>
  <!--Debt Instrument, covenant, leverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantLeverageRatio contextRef="c20140101to20141231_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U005" decimals="INF">3.75</ebs:DebtInstrumentCovenantLeverageRatio>
  <!--Debt Instrument, covenant, leverage ratio-Credit Agreement [Member]-->
  <ebs:DebtInstrumentCovenantLeverageRatio contextRef="c20140101to20140331_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="U005" decimals="INF">3.50</ebs:DebtInstrumentCovenantLeverageRatio>
  <!--Non refundable receipt-Morphosys [Member]-->
  <ebs:NonRefundableReceipt contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="-6">20000000</ebs:NonRefundableReceipt>
  <!--Additional contingent payment-Morphosys [Member]-->
  <ebs:AdditionalContingentPayment contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="-6">163000000</ebs:AdditionalContingentPayment>
  <!--Maximum funding requirement cap-Morphosys [Member]-->
  <ebs:MaximumFundingRequirementCap contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="-6">186000000</ebs:MaximumFundingRequirementCap>
  <!--Tiered royalty obligation specified as percentage-Morphosys [Member]-->
  <ebs:TieredRoyaltyObligationSpecifiedAsPercentage contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U005" decimals="1">0.2</ebs:TieredRoyaltyObligationSpecifiedAsPercentage>
  <!--Number of units of accounting-Morphosys [Member]-->
  <ebs:NumberOfUnitsOfAccounting contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U006" decimals="INF">2</ebs:NumberOfUnitsOfAccounting>
  <!--Allocation of non refundable proceeds to units of accounting-Morphosys [Member]-->
  <ebs:AllocationOfNonRefundableProceedsToUnitsOfAccounting contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="-5">20000000</ebs:AllocationOfNonRefundableProceedsToUnitsOfAccounting>
  <!--Allocation of non refundable proceeds to License unit-Morphosys [Member]-->
  <ebs:AllocationOfNonRefundableProceedsToLicenseUnit contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="-5">15300000</ebs:AllocationOfNonRefundableProceedsToLicenseUnit>
  <!--Allocation of non refundable proceeds to undelivered items unit-Morphosys [Member]-->
  <ebs:AllocationOfNonRefundableProceedsToUndeliveredItemsUnit contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U002" decimals="-5">4700000</ebs:AllocationOfNonRefundableProceedsToUndeliveredItemsUnit>
  <!--Present value factor used for estimating selling price of License-Morphosys [Member]-->
  <ebs:PresentValueFactorUsedForEstimatingSellingPriceOfLicense contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U005" decimals="2">0.12</ebs:PresentValueFactorUsedForEstimatingSellingPriceOfLicense>
  <!--Present value factor used for estimating selling price of Research and Development Services-Morphosys [Member]-->
  <ebs:PresentValueFactorUsedForEstimatingSellingPriceOfResearchAndDevelopmentServices contextRef="c20140701to20140930_TypeOfArrangementAxis_MorphosysMember" unitRef="U005" decimals="2">0.12</ebs:PresentValueFactorUsedForEstimatingSellingPriceOfResearchAndDevelopmentServices>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:footnote xlink:label="Footnote-Item-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Acquired inventory reflects a $6.2 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $6.2 million step-up was estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on estimated inventory turnover, which will increase costs of product sales and contract manufacturing during such period.</link:footnote>
    <link:loc xlink:href="#Item-1" xlink:label="Item-1_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-1_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in cash and cash equivalents in accompanying consolidated balance sheets.</link:footnote>
    <link:loc xlink:href="#Item-2" xlink:label="Item-2_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-2_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-3" xlink:label="Item-3_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-3_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-4" xlink:label="Item-4_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-4_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-5" xlink:label="Item-5_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-5_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-6" xlink:label="Item-6_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-6_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-7" xlink:label="Item-7_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-7_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-8" xlink:label="Item-8_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-8_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:loc xlink:href="#Item-9" xlink:label="Item-9_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-9_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
  </link:footnoteLink>
</xbrl>
